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ABSTRACT
Background. Biomarkers for accurate diagnosis of early
hepatocellular carcinoma (HCC) are limited in number and
clinical validation. We applied SELDI-TOF-MS Protein-
Chip technology to identify serum proﬁle for distinguishing
HCC and liver cirrhosis (LC) and to compare the accuracy
of SELDI-TOF-MS proﬁle and alpha-fetoprotein (AFP)
level in HCC diagnosis.
Patients and Methods. Serum samples were obtained
from 120 HCC and 120 LC patients for biomarker dis-
covery and validation studies. ProteinChip technology was
employed for generating SELDI-TOF proteomic features
and analyzing serum proteins/peptides.
Results. A diagnostic model was established by CART
algorithm, which is based on 5 proteomic peaks with m/z
values at 3324, 3994, 4665, 4795, and 5152. In the training
set, the CART algorithm could differentiate HCC from LC
subjects with a sensitivity and speciﬁcity of 98% and 95%,
respectively. The results were assessed in blind validation
using separate cohorts of 60 HCC and 60 LC patients, with
an accuracy of 83% for HCC and 92% for LC patients. The
diagnostic odd ratio (DOR) indicated that SELDI-TOF
proteomic signature could achieve better diagnostic per-
formance than serum AFP level at a cutoff of 20 ng/mL
(AFP20) (92.72 vs 9.11), particularly superior for early-
stage HCC (87% vs 54%). Importantly, a combined use of
both tests could enhance the detection of HCC (sensitivity,
95%; speciﬁcity, 98%; DOR, 931).
Conclusion. Serum SELDI-TOF proteomic signature,
alone or in combination with AFP marker, promises to be a
good tool for early diagnosis and/screening of HCC in at-
risk population with liver cirrhosis.
Hepatocellular carcinoma (HCC) is the ﬁfth most com-
mon cancer worldwide with China and North America
showing a continuous increase in incidence and mortality
rate.
1 The prognosis of HCC remains poor, and most
patients have a 5-year survival rate of less than 5% mainly
because of the late diagnosis.
2 Evidence suggests that sur-
gical resection, liver transplantation, and other curative
therapies, such as ablative treatments, can signiﬁcantly
improve the survival for those HCC patients with tumor
detected at an early stage.
3,4 Early diagnosis, therefore, is of
paramount importance for prolonging the survival of HCC
patients. Chronic hepatitis-relatedliver cirrhosis (LC) is one
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DOI 10.1245/s10434-010-1038-8of the strongest predisposing factor, and *60 to 80% of
cirrhotic patients inevitably develop HCC. Therefore, early
detection of HCC by incorporation of surveillance program
for high-risk populations, such as those with LC or hepatitis
carriers, can improve outcomes of HCC patients.
5,6
Detection of serum alpha-fetoprotein (AFP) level (at a
cutoff of 20 ng/mL, AFP20) and ultrasonography of intra-
hepatic lesions are the 2 most common clinical approaches
to detect HCC.
7 However, these two methods suffer from
certain limitations. For instance, ultrasound imaging is
highly operator dependent and is not sensitive enough to
detect liver tumors in patients with cirrhotic background.
8
Serum AFP level is insensitive, such that about one-third of
early-staged HCC patients with small tumors (\3 cm) show
same level of AFP as those in healthy subjects, making it
useful only to identify late-staged HCC patients. Besides,
high false-positive rate is found in *20% of the patients
with chronic hepatitis and in 20–50% of those with LC.
2,9 In
this regard, there is an urgent need to identify alternative
serum biomarkers for early detection of HCC.
10–12
For serum proteomics, surface-enhanced desorption/ion-
ization time-of-ﬂight mass spectrometry (SELDI-TOF-MS)
ProteinChip technology provides an efﬁcient and sensitive
means for biomarker discovery. It enables quantitative
measurement of speciﬁc peptide/protein in a high-through-
put way, and small amount of materials are required for the
analysis. All these features make SELDI-TOF-MS an
attractive tool for clinical application. This technology has
been successfully applied to facilitate biomarker discovery
for various malignancies, such as breast cancer, ovarian
cancer, lung cancer, nasopharyngeal cancer, and colorectal
cancer.
13–19Inaddition,thisapproachhasbeenusedtostudy
diagnostic biomarkers and/or proteomic patterns for
HCC.
20–22 However, these earlier SELDI-TOF-MS-based
HCC studies had small sample sizes, and the patients
involved were mainly in advanced stages. Therefore, we
intended to investigate the serum ﬁngerprint speciﬁcally
associated with hepatitis B-related LCand early-stageHCC.
In addition, we compared the accuracy of using this serum
patterns with the conventional AFP biomarkers for differ-
entiating early-staged HCC and LC patients.
MATERIALS AND METHODS
Patients and Sample Collection
A total of 240 patient subjects (120 HCC patients and
120 LC patients) were included in this study, and these
patients were presented to the Queen Mary Hospital
(Pokfulam, Hong Kong) between 2003 and 2005. The
demographics and clinicopathological data are summarized
in Table 1. Informed consent was obtained from these
patients. This study was approved by the Joint University/
Hospital Authority’s Institutional Review Board. All
patients were age- and gender-matched Chinese having
the same HBsAg proﬁle. Preliminary diagnosis of HCC
was based on preoperative investigations, which included
blood biochemistry, AFP assay, chest x-ray, percutane-
ous ultrasonography, computed tomography, and hepatic
angiography in selected patients. Liver function was
assessed using Child-Pugh classiﬁcation. Histopathological
examination of the resected specimens was conducted by
board-certiﬁed pathologists to conﬁrm the diagnosis.
Tumor stages were based on the AJCC staging system.
Early HCC was deﬁned as stage I (T1N0M0). Diagnosis of
cirrhosis was based on liver histology as well as laboratory
and imaging evidence of hepatic decompensation or portal
hypertension. The median follow-up period of cirrhotic
patients was 12 months with no sign of HCC development.
The training set consisted of 60 subjects with patholog-
ically validated LC but without HCC and 60 HCC patients
who were mainly at AJCC stage I and II (70%). Another 60
LC and 60 HCC patients were included in the blinded val-
idation set. Pooled serum samples from healthy subjects
were used as interassay quality control. Blood samples were
taken prior to surgery and 3 months after surgery. Extracted
serum was stored at -80C. A commercial chemilumines-
cent immunoassay kit (ACS 180SE, Bayer, Leverkuesen,
Germany) was used to determine the serum AFP level. In
clinical practice, the upper normal range of AFP was 8–
10 ng/mL and patients having[20 ng AFP/mL were con-
sidered to have liver abnormality. Therefore, this same AFP
cutoff level was used in the current study to discriminate
HCC in high-risk populations.
23
SELDI-TOF-MS and Data Analysis
Serum samples were thawed completely and centrifuged
to remove debris at 9600 g for 10 min at 4C. SELDI-
TABLE 1 Clinical features of patient cohort
Group HCC (n = 120) Cirrhosis (n = 120)
Sex (M/F) 96/24 88/32
Age (year) 55.4 ± 11.4 50.9 ± 12.6
HBsAg (?) 100 106
AFP 17580.8 ± 100941.3 24.5 ± 90.8
\20 ng/mL (%) 37 (30.8%) 94 (78.3%)
20–400 ng/mL (%) 28 (23.3%) 25 (20.8%)
C400 ng/mL (%) 55 (45.8%) 1 (0.8%)
Tumor stage (I/II/III/IV) 46/36/38/0 NA
n number, HBsAg (?) hepatitis B virus antigen positive,
AFP alpha-fetoprotein, NA not applicable
Note: All data are presented as mean ± SD
Early Diagnosis of HCC By Serum Proﬁling 2519TOF-MS proﬁling using the IMAC-3 chip (Ciphergen
Biosystems, Fremont, CA) was done as previously descri-
bed.
18,22 In brief, 5 lL of the cleared serum was mixed
with 5 lL phosphate-buffered saline (PBS) containing 8 M
urea and 2% CHAPS and then diluted with 108 lL binding
buffer (0.25 M sodium chloride and 1% CHAPS in PBS).
After that, 100 lL of diluted serum samples were loaded
on each array spot with a robotic bioprocessor and incu-
bated for 1 h at room temperature. After washing off
unbound molecules, each array was spotted twice with
0.5 lL of freshly prepared EAM matrix solution (sinapinic
acid saturated with 0.5% triﬂuoroacetic acid and 50%
acetonitrile).
Mass spectrometric analysis was performed by SELDI-
TOF-MS in a PBS-IIc ProteinChip reader (Ciphergen Bio-
systems)accordingtoanautomateddatacollectionprotocol.
Serumspectrumwasgeneratedbyaveragingtheresultsof65
laser shotsatalaser intensityof240, adetectorsensitivity of
8, in which the qualiﬁed mass peaks (signal-to-noise ratio
[5) with mass-to-charge ratios (m/z) in an optimized range
of 3000–12,500 Da were detected. Spectral analysis was
carried out by the Biomarker Wizard program (version 3.1;
Ciphergen Biosystems). After the total ion current normal-
ization, the spectra data of the training set was analyzed
using the Biomarker Pattern software (version 4.1, Cipher-
gen Biosystems) for model building. A classiﬁcation and
regression tree (CART) analysis was performed, as previ-
ously described, based on the differentially expressed
protein peaks in sera of LC and HCC patients.
24
The construction of CART included 2 steps, namely the
tree construction step and the tree pruning step. For the tree
construction process, the BPS was used to search for the
best peak with deﬁned cutoff level so that the training
dataset was split into two daughter nodes. The splitting
decision was based on the peak intensity of a sample.
Samples went to the left daughter node if their peak
intensities were equal to or less than the cutoff intensity
value; otherwise, the samples would go to the right
daughter node. The software continued to repeat this
splitting process on each daughter node in this manner until
no further gain in the classiﬁcation was achieved and ter-
minal nodes were produced. Classiﬁcation of the terminal
nodes was decided by a group of samples (i.e., HCC and
LC), which represented the majority of samples in that
group. In the second step of CART, the classiﬁcation tree
was cut down to a desired size that yielded the least clas-
siﬁcation error. In this study, a decision tree was generated
using the Gini method with nonlinear combinations. A 10-
fold cross-validation test was used for the evaluation of the
classiﬁcation error. The performance of the classiﬁcation
algorithm was then challenged in a blind study in which the
test set consisted of a new batch of 120 serum samples (60
samples from each group).
Statistical Analysis
Sensitivity was calculated as the ratio of the number of
HCC samples that were correctly classiﬁed as HCC (true
positive) to the total number of HCC samples. Speciﬁcity
was calculated as the ratio of the number of LC samples
that were correctly classiﬁed as LC (true negative) to the
total number of LC samples. The diagnostic odds ratio of a
test was the ratio of the odds of positivity in HCC relative
to the odds of positivity in the LC. The correlation analysis
compared with clinical features, relative peak intensity
levels between two groups was calculated using indepen-
dent samples t test. For comparison of sensitivity and
speciﬁcity of CART and AFP level, 2 independent sample
chi-square tests were used. The correlation analysis
between clinical features and peak intensity levels was
calculated using bivariate correlation analysis. All the
calculations were completed with the SPSS statistical
package (SPSS Inc., Chicago, IL).
RESULTS
Stability and Reproducibility of the SELDI-TOF-MS
Spectra
Pooled normal sera, which were spotted randomly on
different chips, were used to test for the consistency of the
SELDI-TOF-MS spectra among different protein chips.
The coefﬁcients of variance (CV) for the three highest
peaks with relative intensities above 25 were \20%, and
their m/z ratios were \0.1%, akin to that of other stud-
ies.
25,26 This suggested that little variation in the protein
spectra was present for the same sample among different
chips, implicating the stability and reproducibility of the
SELDI-TOF-MS spectra.
CART and Its Performance
The serum spectra from 60 HCC and 60 LC subjects
were used as the training set. After intensity normalization,
80 peaks were found to be statistically signiﬁcant between
HCC and LC patients (P\.05). Five protein peaks were
regarded as classiﬁers to construct the CART. Figure 1a
represents spectral views showing some of these protein
peaks in the HCC sera compared with the LC sera. The
spreadsheets of normalized intensities of these peaks were
exported into the Biomarker Patterns software for CART
analysis. Of the many classiﬁcation trees generated by
using different settings of Gini, advance, cost of BPS
software, the most optimal classiﬁcation tree with lowest
error cost was eventually established. A CART with 6
terminal nodes was established, based on the 5 discrimi-
native peaks with m/z of 3324, 3994, 4665, 4795, and 5152
2520 L. Chen et al.that could separate HCC patients from LC patients
(Table 2) (Fig. 1b). When the 5 proteomic peaks were used
as classiﬁers, this CART algorithm would yield an accu-
racy rate of 96.7% (116 of 120), a sensitivity of 98.33%,
and a speciﬁcity of 95% for predicting HCC in the training
set. To validate the above ﬁnding, a blinded set consisting
of a separate cohort of 60 HCC patients and 60 LC patients
was used. Serum protein proﬁles of these samples were
collected and treated the same as those in the training set.
The normalized peak intensities in the blinded set were
subjected to analysis. A sensitivity of 83% (50 of 60), a
speciﬁcity of 92% (55 of 60), and an accuracy rate of
87.5% were yielded in the blind set. Also, 87% (40 of 46)
of the HCC patients in stage I and 89% of patients in stage
II were detected by the classiﬁcation algorithm (Table 3).
Changes in Serum Proteomic Features Before
and After Surgery
To strengthen these ﬁndings, we performed additional
experiments to determine the change of proteomic proﬁles
in 10 pairs of serum samples collected from newly
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FIG. 1 a Trace view (above) and
gel view (under) of representative
SELDI-TOF-MS spectra of serum
samples from HCC and cirrhosis
patients in the range from m/z
3750 to 5000. The three major
discriminative peaks at m/z 3994,
4665, and 4795 in the
classiﬁcation tree are pointed out
by arrows, respectively. b The
optimal classiﬁcation tree
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a terminal with designed class
outcome—(dark circle), HCC, or
(gray square), LC
Early Diagnosis of HCC By Serum Proﬁling 2521recruited HCC patients, before and 3 months after surgery.
As shown in Fig. 2a, there is a decrease of the serum level
of m/z 3324 peak after removal of the tumors. Although the
difference is not signiﬁcant (P = .131), there is a trend of
declination in the serum from the postsurgery group.
Interestingly, the serum level of m/z 4795 peak, which was
initially lower in the HCC group than the LC group, was
signiﬁcantly increased after surgery (P = .01) (Fig. 2b).
Comparison of SELDI-TOF-MS Pattern and AFP Level
for Early-Stage HCC Diagnosis
The sensitivity and speciﬁcity of SELDI-TOF-MS pat-
tern and AFP20 to predict different stages of HCC were
examined in 120 HCC patients from training and validation
set. A sensitivity of 87% (40 of 46) for detecting stage I
HCC patients, 89% (32 of 36) for detecting stage II and
97% (37 of 38) for detecting late-staged HCC patients
(stage III) were obtained by CART analysis (Table 3).
When AFP20 was used to predict HCC stages, a sensitivity
of 54% (25 of 46) for stage I HCC patients, 72% (26 of 36)
for stage II HCC, and 84% (32 of 38) for late-staged HCC
patients (stage III) were obtained, which was less favorable
than CART, especially for detecting stage I HCC
(P\.05). The diagnostic odds ratios (DOR) were also
calculated in this study to compare the CART analysis and
AFP20 (Table 4) for predicting HCC in the blinded sam-
ples. DOR is a single indicator for diagnostic performance,
such that higher DOR value means better discriminative
power.
27 The calculated DOR of CART algorithm was
92.72, implying that the odds for positivity among patients
with HCC was 92.72 times higher than the odds for posi-
tivity among patients without HCC. The calculated DOR
for AFP20 was 9.11 only. Based on these values, CART
algorithm performed 10 times better than AFP20 in
detecting HCC from LC patients (92.72 vs 9.11) (Table 4).
Interestingly, a combined use of both CART and AFP20
increased the sensitivity to 95%, with at least 1 of the 2
tests being positive, and the speciﬁcity to 98%, when both
tests were negative. The estimated DOR was 931 for the
combined tests, which was better than the individual test
alone (931 vs 92.72 and 9.11) (Table 4). Despite that, no
signiﬁcant correlation was found between the intensity
values of each discriminative peak and some of the clini-
copathological data of HCC patients—age, sex, AFP level,
tumor size, and tumor stage (data not shown).
DISCUSSION
Inthisstudy,weproﬁled240serum proteomes(120HCC
and 120 LC) to identify distinctive patterns as a ﬁngerprint
for predicting HCC. Most of the clinical samples were
obtained from early-staged HCC patients, implicating the
potential application of the derived results in clinical set-
tings to identify HCC at its early stage. Diagnosis of HCC at
earlystageisbeneﬁcialforpatients asearlydiagnosismeans
better prognosis. Importantly, the experimental procedure
described in this study did not involve prefractionation and
albumin depletion, which were currently adopted for
studying serum and inevitably might eliminate low abun-
dance and low molecular weight disease markers. Use of
serum without pretreatment also enables the process to be
high throughput and cost effective.
Serum proﬁling is an attractive approach for ﬁnding
markers or patterns for cancer diagnosis. HCC progression
associates with proteomic changes, which may be partially
reﬂected based on the changes in the blood composition of
patients. Sometimes, proteins are secreted by tumor cells or
by other organs in response to the presence of cancer or the
hallmark of predisposing factors to HCC occurrence. Our
initial efforts to identify the 5 proteomic peaks revealed the
candidate markers as (m/z 3324) relaxin B chain (RLN2,
P04090), (m/z 3994) neuropeptide K (TAC1, P20366), (m/z
4665) unidentiﬁed, and (m/z 4795) PACAP-related peptide
or PRP-48 (ADCYAP, P18509), and (m/z 5152) Comple-
ment C3 g fragment (CPAMD1, P01024). Subsequently,
we further investigated the gene expression levels of RLN2
(m/z 3324), TAC1 (m/z 3994), and PACA (m/z 4795) in 10
pairs of HCC and adjacent nontumor tissues by microarray
analysis (Wong et al., unpublished data). We found RLN2
was overexpressed in the tumor tissues, whereas the
ADCYAP1 level was downregulated. However, there was
TABLE 2 Intensities of ﬁve discriminative peaks
m/zP value HCC group Cirrhosis group
3994 \.000001 16.98 ± 6.17 8.36 ± 4.50
4665 \.000001 19.57 ± 9.84 7.88 ± 5.22
4795 .0000568 2.24 ± 1.35 4.17 ± 3.22
3324 .007 3.13 ± 5.78 1.80 ± 1.44
5152 .0000036 4.94 ± 2.42 2.99 ± 1.50
m/z mass-to-charge ratio
Note: All data are presented as mean ± SD
TABLE 3 Number of HCC patients at different stages identiﬁed by
serum SELDI-TOF-MS pattern and AFP20
Tumor
stage
Number of
patients
SELDI-TOF-MS pattern
(n/%)
AFP20 (n/%)
I 46 40/87% 25/54%*
II 36 32/89% 26/72%
III 38 37/97% 32/84%
Total 120 109/91% 83/69%
Note: AFP20, at a cutoff value[20 ng/mL
* Compared with SELDI-TOF-MS, P\.05
2522 L. Chen et al.no signiﬁcant difference in TAC1 expression between
tumor and nontumor tissues. We suggest that neuropeptide
K may not be directly released from the tumors, and its
level may reﬂect the host response to the tumor develop-
ment and progression.
Because of the noninvasive nature of obtaining serum
when compared with other means, such as ﬁne-needle
biopsy, the information derived from serum analysis can
probably have clinical implications and applications.
Recent studies suggest that a single biomarker is not
effective in detecting cancers. Therefore, current biomarker
research is shifting from analyzing 1 marker to the simul-
taneous measurement of several biomarkers.
28 SELDI-
TOF-MS is one of the proﬁling approaches enabling the
simultaneous analysis of several markers or peaks and is
particularly useful for analyzing serum proteomes and
potentially applicable for intraoperative biomarkers assays
during surgery.
29 For instance, Paradis et al. demonstrated
a fragmented form of vitronectin as a novel serum marker
for HCC using SELDI-TOF-MS.
30 In addition, Cui et al.
used WCX2 protein chips to generate the serum protein
proﬁles to discriminate patients with hepatitis B, LC, or
HCC.
21
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FIG. 2 Changes in serum proteomic features before and after surgery
by SELDI-TOF-MS. Zoom-in spectrum of m/z 3324 a and m/z 4795 b
in 10 pairs of HCC serum samples before (left panel) and 3 months
(right panel) after surgery. The speciﬁc proteomic features were
indicated by red lines. The lower panel was the normalized intensities
of the speciﬁc peak in the preoperative group plotted against the
postoperative group, and the statistical signiﬁcance was calculated by
t test
TABLE 4 Sensitivity, speciﬁcity, and DOR of individual and/or
combined use of SELDI-TOF-MS pattern and AFP20 for HCC
diagnosis
Test Sensitivity (%) Speciﬁcity (%) DOR
SELDI-TOF-MS 83 95 92.72
AFP20 72 78 9.11
SELDI-TOF-MS
and/or AFP20
95 98 931
AFP20 AFP at a cutoff value[20 ng/mL. DOR diagnostic odd ratios
DOR = sensitivity/(1-sensitivity)/(1-speciﬁcity)/speciﬁcity
Early Diagnosis of HCC By Serum Proﬁling 2523In accordance with other studies, we also found distinct
serum proﬁles generated by SELDI-TOF-MS between hep-
atitis B-related HCC and LCthat can be used todifferentiate
these 2 patient groups. Using the same patient cohort, we
found that SELDI-TOF-MS indeed performed better than
clinicallyusedAFP20todiagnoseHCC,especiallyforearly-
staged HCC. Zinkin et al. performed a similar study to
compare detection accuracy of using SELDI-TOF-MS and
AFP20 to predict HCC using patients with hepatitis C back-
ground. They also demonstrated a higher sensitivity and
speciﬁcity for HCC detection associated with the use of
SELDI-TOF-MS when compared with AFP20, such that the
sensitivity/speciﬁcity for AFP20 and SELDI-TOF-MS were
73%/71% and 79%/86%, respectively.
31 Though their study
differed from ours in the etiology of HCC patients (HCV
related vs HBV related in this study), both studies demon-
strated that serum SELDI-TOF-MS pattern employing a
combinationofseveralbiomarkerswassuperiorindetecting
HCCthantheknownserumbiomarker.Importantly,thebest
result for detecting HCC patients from LC patients was
achieved when serum SELDI-TOF-MS pattern was com-
bined with serum AFP detection.
There were previous concerns about the reproducibility
of SELDI-TOF-MS technology.
32 Because of the different
experimental setups, the SELDI-TOF-MS patterns might
be different for different laboratories. Still, we believe that
SELDI-TOF-MS pattern is a viable means for clinical
diagnosis of HCC if the assays are done in high-standard
reference laboratories following stringent optimized stan-
dard operation procedures and integrated with robotic
automation. The next critical step is clinical validation in
multiple centers. Importantly, Kanmura et al. also dem-
onstrated the capability of using SELDI-TOF-MS patterns
to diagnose 6 of 7 HCC patients, for which these patients
were later conﬁrmed to have HCC by ultrasonography.
33 In
conclusion, our study shows that serum SELDI-TOF-MS
proﬁle can be used to differentiate HCC patients, even the
early-staged, from cirrhotic subjects with higher sensitivity
and speciﬁcity than the clinically used AFP level.
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